We report the efficacy, tolerability and cost of erythocytoapheresis plus recombinant human erythropoietin (rHuEPO) in three patients with severe hereditary hemochromatosis (HH). Results indicate that this regimen could be a valid therapeutic alternative in complicated HH patients. Its cost, however, limits its use to patients whose clinical conditions prevent a proper phlebotomy regimen.

Mariani, R., Pelucchi, S., Perseghin, P., Corengia, C., & Piperno, A. (2005). Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage. HAEMATOLOGICA, 90(5), 717-718.

Erythrocytapheresis plus erythropoietin: An alternative therapy for selected patients with hemochromatosis and severe organ damage

MARIANI, RAFFAELLA;PELUCCHI, SARA;PIPERNO, ALBERTO
2005

Abstract

We report the efficacy, tolerability and cost of erythocytoapheresis plus recombinant human erythropoietin (rHuEPO) in three patients with severe hereditary hemochromatosis (HH). Results indicate that this regimen could be a valid therapeutic alternative in complicated HH patients. Its cost, however, limits its use to patients whose clinical conditions prevent a proper phlebotomy regimen.
Articolo in rivista - Articolo scientifico
erythrocytapheresis, erythropoietin, hemochromatosis
English
717
718
2
Mariani, R., Pelucchi, S., Perseghin, P., Corengia, C., & Piperno, A. (2005). Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage. HAEMATOLOGICA, 90(5), 717-718.
Mariani, R; Pelucchi, S; Perseghin, P; Corengia, C; Piperno, A
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/4069
Citazioni
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 28
Social impact